Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in L'hospitalet De Llobregat – page 270

3 655 clinical trials in L'hospitalet De Llobregat, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
L'hospitalet De Llobregat at a glance
3 655
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

3 655 trials in L'hospitalet De Llobregat

Open in trial search

Infertility

Not recruiting

Study on Infertility: Comparing Corifollitropin Alfa and Follitropin Beta for Women Undergoing Elective Fertility Preservation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Corifollitropin Alfa
  • Sponsor:Santiago Dexeus Font Fundacio Privada

Squamous cell carcinoma of head and neck

Not recruiting

Study of Tislelizumab, Surzebiclimab, and LBL-007 for Patients with Recurrent or Metastatic Head and Neck Cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:LBL-007
  • Sponsor:BeOne Medicines AG

Acute myocardial infarction

Not recruiting

Study to Test BI 765845 for Patients with Heart Attack

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:BI 765845
  • Sponsor:Boehringer Ingelheim Espana S.A.

Kidney transplant rejection

Not recruiting

Study on Tegoprubart for Preventing Kidney Transplant Rejection in Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Mycophenolic Acid
  • Sponsor:Eledon Pharmaceuticals Inc.

Endometrial cancer+6

Not recruiting

Study on Pembrolizumab, Lenvatinib, and Belzutifan for Patients with Liver, Colon, Pancreatic, Bile Duct, Gallbladder, Endometrial, or Esophageal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

IgA nephropathy

Not recruiting

Study on the Safety and Effectiveness of Atrasentan for Patients with IgA Nephropathy Taking SGLT2 Inhibitors

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Novartis Pharma AG

Colorectal adenocarcinoma

Not recruiting

Study on the Effectiveness and Safety of Cetuximab, Encorafenib, and Binimetinib for Patients with Advanced Colorectal Cancer with BRAF V600E Mutation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Asociacion Grupo Tratamiento De Tumores Digestivos

Pancreatic carcinoma+3

Not recruiting

Study on BI 907828 for Patients with Advanced Biliary Tract, Pancreatic, Lung, or Bladder Cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Boehringer Ingelheim Espana S.A.

Gingival bleeding+1

Not recruiting

Study on Tranexamic Acid Oral Solution for Preventing Bleeding in Patients on Blood Thinners Undergoing Tooth Extraction

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tranexamic Acid
  • Sponsor:Hyloris Developments

IgA nephropathy

Not recruiting

Study on the Long-term Safety and Effectiveness of Sibeprenlimab for Patients with Immunoglobulin A Nephropathy (IgAN)

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sibeprenlimab
  • Sponsor:Otsuka Pharmaceutical Development And Commercialization Inc.

Clear cell renal cell carcinoma

Not recruiting

Study of Belzutifan and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

HIV infection

Not recruiting

Study Comparing Integrase Inhibitor (Bictegravir) and Boosted Protease Inhibitor (Darunavir) Treatments for Patients with Advanced HIV Infection

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:NEAT ID Foundation

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in L'hospitalet De Llobregat

What the registry says about research in the country

01 Infectious Disease Prevention

Innovative research focused on vaccine development targeting multiple infectious diseases, including studies on UTI prevention, yellow fever, and RSV protection in adults.

  • UTI Vaccine Safety & Efficacy
  • Yellow Fever Immunization
  • RSV Protection Studies

These trials aim to enhance vaccine effectiveness and improve public health outcomes through preventive measures.

02 Oncology Research

Comprehensive studies exploring new treatments for various types of advanced cancers, with particular focus on targeted therapies and novel drug combinations.

  • Colorectal Cancer Treatment
  • Gastric Cancer Therapies
  • Pancreatic Cancer Interventions

Advanced clinical research investigating innovative approaches to combat various forms of cancer.

03 Transplant Medicine

Groundbreaking research in kidney transplantation, focusing on preventing rejection and improving post-transplant outcomes.

  • Antibody-Mediated Rejection
  • Delayed Graft Function
  • Novel Immunosuppressive Approaches

Studies aimed at enhancing transplant success rates and patient recovery.

04 Autoimmune Conditions

Clinical investigations into treatments for various autoimmune disorders, including innovative therapies for inflammatory conditions.

  • Psoriatic Arthritis Treatment
  • Atopic Dermatitis Management
  • Myasthenia Gravis Therapy

Focused on developing targeted treatments to improve patient quality of life.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.